...
首页> 外文期刊>Arteriosclerosis, thrombosis, and vascular biology >Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice.
【24h】

Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice.

机译:Toll样受体4参与人和小鼠静脉移植物的重塑,局部基因沉默可减少高胆固醇血症APOE * 3Leiden小鼠的静脉移植物疾病。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The goal of this study was to explore the role of Toll-like receptor 4 (TLR4) in vein graft remodeling and disease. METHODS AND RESULTS: First, expression of TLR4 was analyzed in freshly isolated human saphenous veins (huSV), in freshly isolated huSV ex vivo perfused in an extracorporeal circulation, or in huSV used as coronary vein grafts. Marked induction of focal TLR4 expression was observed in perfused fresh huSV. Moreover, TLR4 was abundantly present in lesions in fresh huSV or in intimal hyperplasia in coronary vein grafts. Second, mouse venous bypass grafting was performed. In grafts of hypercholesterolemic APOE*3Leiden mice, increased TLR4 mRNA and protein was detected over time by reverse transcription-polymerase chain reaction and immunohistochemistry. Furthermore, the local presence of the endogenous TLR4 ligands heat shock protein 60, high-mobility group box 1, tenascin-C, and biglycan in the grafts was demonstrated. TLR4 deficiency in C3H-Tlr4LPS-d (LPS indicates lipopolysaccharide) mice resulted in 48+/-12% less vein graft wall thickening (P=0.04) than in Balb/c controls. Moreover, local TLR4 gene silencing in hypercholesterolemic APOE*3Leiden mice using lentiviral short hairpin RNA against TLR4 administered perivascularly around vein grafts led to a 44+/-13% reduction of vessel wall thickening compared with controls (P=0.0059). CONCLUSIONS: These results indicate that TLR4 is involved in vein graft remodeling and can be used as a local therapeutic target against vein graft disease.
机译:目的:本研究旨在探讨Toll样受体4(TLR4)在静脉移植物重塑和疾病中的作用。方法和结果:首先,分析TLR4在新鲜分离的人隐静脉(huSV),体外循环体内灌注的新鲜分离的huSV或用作冠状静脉移植物的huSV中的表达。在灌注的新鲜huSV中观察到局灶TLR4表达的明显诱导。此外,TLR4大量存在于新鲜huSV的病变或冠状静脉移植物中的内膜增生中。其次,进行小鼠静脉旁路移植术。在高胆固醇血症APOE * 3Leiden小鼠的移植物中,通过逆转录-聚合酶链反应和免疫组织化学检测到随着时间的推移,TLR4 mRNA和蛋白增加。此外,证实了移植物中局部存在内源性TLR4配体热休克蛋白60,高迁移率族框1,肌腱蛋白-C和双糖链蛋白聚糖。与Balb / c对照相比,C3H-Tlr4LPS-d(LPS表示脂多糖)小鼠中的TLR4缺乏导致静脉移植物壁增厚少48 +/- 12%(P = 0.04)。此外,使用抗TLR4的慢病毒短发夹RNA对高胆固醇血症型APOE * 3Leiden小鼠进行局部静脉TLR4基因沉默处理,与对照组相比,血管壁增厚减少了44 +/- 13%(P = 0.0059)。结论:这些结果表明TLR4参与静脉移植物的重塑,并且可以用作针对静脉移植物疾病的局部治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号